Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Dynavax Technologies Corp (NASDAQ:DVAX)

Tuesday’s trading has closed, but DVAX is being traded in the after-hours session. After-Hours quote »
Delayed Data
As of 3:59pm ET
 -0.30 / -1.08%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Dynavax Technologies Corp. is a clinical-stage biopharmaceutical company that uses toll-like receptor TLR biology to discover and develop novel vaccines and therapeutics. The company's development programs are organized under its three areas of focus: vaccine adjuvants, cancer immunotherapy, and autoimmune and inflammatory diseases. Its lead product candidate is HEPLISAV, a Phase III investigational adult hepatitis B vaccine. The company's other products under pipeline are SD-101, DV1179 Autoimmune Disease and AZD1419 Asthma Therapy. Dynavax Technologies was founded by Lawrence M. Lichtenstein, Dennis A. Carson and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA.

Contact Information

Dynavax Technologies Corp.
2929 Seventh Street
Berkeley California 94710-2753
P:(510) 848-5100
Investor Relations:



Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Eddie J. GrayChief Executive Officer & Director
David F. NovackSenior Vice President-Operations & Quality
Michael S. OstrachCFO, Secretary, Chief Business Officer & VP
Robert L. CoffmanChief Scientific Officer & Senior Vice President
Robert JanssenChief Medical Officer & VP-Clinical Development